Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Becky Kinkead

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
The American Journal of Psychiatry|February 16, 2019
Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting DepressionBoadie W Dunlop, Devon LoParo, Becky Kinkead, et al.
Personalized Medicine in Psychiatry|August 8, 2022
The United States index of socioeconomic deprivation for individuals (USiDep)Boadie W Dunlop, Jeffrey J Rakofsky, David Mischoulon, et al.
Psychiatry Research|November 3, 2007
Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapyLinda L Carpenter, Lily Bayat, Francisco Moreno, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 12, 2023
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediatorsStefania Lamon-Fava, Minying Liu, Boadie W Dunlop, et al.
The American Journal of Psychiatry|March 25, 2017
Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive DisorderBoadie W Dunlop, Justin K Rajendra, W Edward Craighead, et al.
The American Journal of Psychiatry|March 25, 2017
Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) StudyBoadie W Dunlop, Mary E Kelley, Vivianne Aponte-Rivera, et al.
Brain, Behavior, & Immunity - Health|July 28, 2023
Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trialNaoise Mac Giollabhui, David Mischoulon, Boadie W Dunlop, et al.
Journal of Psychiatric Research|June 22, 2013
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorderSteven J Garlow, Becky Kinkead, Michael E Thase, et al.
The Journal of Clinical Psychiatry|January 7, 2011
Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetineOmer Bonne, Jessica Mary Gill, David A Luckenbaugh, et al.
The American Journal of Psychiatry|April 6, 2006
Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depressionThomas D Geracioti, Linda L Carpenter, Michael J Owens, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
The American Journal of Psychiatry|February 16, 2019
Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting DepressionBoadie W Dunlop, Devon LoParo, Becky Kinkead, et al.
Personalized Medicine in Psychiatry|August 8, 2022
The United States index of socioeconomic deprivation for individuals (USiDep)Boadie W Dunlop, Jeffrey J Rakofsky, David Mischoulon, et al.
Psychiatry Research|November 3, 2007
Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapyLinda L Carpenter, Lily Bayat, Francisco Moreno, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 12, 2023
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediatorsStefania Lamon-Fava, Minying Liu, Boadie W Dunlop, et al.
The American Journal of Psychiatry|March 25, 2017
Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive DisorderBoadie W Dunlop, Justin K Rajendra, W Edward Craighead, et al.
The American Journal of Psychiatry|March 25, 2017
Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) StudyBoadie W Dunlop, Mary E Kelley, Vivianne Aponte-Rivera, et al.
Brain, Behavior, & Immunity - Health|July 28, 2023
Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trialNaoise Mac Giollabhui, David Mischoulon, Boadie W Dunlop, et al.
Journal of Psychiatric Research|June 22, 2013
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorderSteven J Garlow, Becky Kinkead, Michael E Thase, et al.
The Journal of Clinical Psychiatry|January 7, 2011
Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetineOmer Bonne, Jessica Mary Gill, David A Luckenbaugh, et al.
The American Journal of Psychiatry|April 6, 2006
Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depressionThomas D Geracioti, Linda L Carpenter, Michael J Owens, et al.
Pageof 5